Z
Zhimin Shao
Researcher at Fudan University
Publications - 162
Citations - 6536
Zhimin Shao is an academic researcher from Fudan University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 32, co-authored 158 publications receiving 4321 citations. Previous affiliations of Zhimin Shao include Fudan University Shanghai Medical College & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz,Chiun Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,P Rastogi,Andreas Schneeweiss,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter A. Fasching,John Crown,Pia Wülfing,Zhimin Shao,Elena Rota Caremoli,Haiyan Wu,Lisa H. Lam,David Tesarowski,Melanie C. Smitt,Hannah Douthwaite,Stina M. Singel,Charles E. Geyer +28 more
TL;DR: Among patients with HER2‐positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T‐DM1 than with trastuzumab alone.
Journal ArticleDOI
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano,Harold J. Burstein,Eric P. Winer,Michael Gnant,Peter Dubsky,Sibylle Loibl,Marco Colleoni,Meredith M. Regan,Martine Piccart-Gebhart,H.-J. Senn,Beat Thürlimann,Fabrice Andre,José Baselga,Jonas Bergh,Hervé Bonnefoi,Sara Y. Brucker,Fatima Cardoso,Lisa A. Carey,Eva Ciruelos,Jack Cuzick,Carsten Denkert,A. Di Leo,Bent Ejlertsen,Prudence A. Francis,Viviana Galimberti,Judy Garber,Bahadir M. Gulluoglu,Pamela J. Goodwin,Nadia Harbeck,Daniel F. Hayes,Chiun-Sheng Huang,Jens Huober,H. Khaled,Jacek Jassem,Zefei Jiang,Per Karlsson,Monica Morrow,Roberto Orecchia,Kent Osborne,Olivia Pagani,Ann H. Partridge,Kathleen I. Pritchard,Jungsil Ro,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Zhimin Shao,I.E. Smith,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Toshihiro Watanabe,Timothy J. Whelan,Bo Xu +53 more
TL;DR: The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer, and recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.
Journal ArticleDOI
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt,Judy Garber,Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmaña,Susan M. Domchek,Karen A. Gelmon,Simon J. Hollingsworth,Larissa A. Korde,Barbro Linderholm,Hanna Bandos,Hanna Bandos,Elżbieta Senkus,Jennifer Marie Suga,Zhimin Shao,Andrew W. Pippas,Zbigniew Nowecki,Tomasz Huzarski,Patricia A. Ganz,Peter Lucas,Peter Lucas,Nigel Baker,Sibylle Loibl,Robin McConnell,Martine Piccart,Rita K. Schmutzler,Guenther G. Steger,Joseph P. Costantino,Amal Arahmani,Norman Wolmark,Norman Wolmark,Eleanor McFadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Greg Yothers,Christine Campbell,Charles E. Geyer +43 more
TL;DR: In this paper, a poly(adenosine diphosphate-ribose) polymerase inhibitor was proposed to target cancers with defects in homologous recombination repair by synthetic lethality.
Journal ArticleDOI
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
John F.R. Robertson,Igor Bondarenko,Ekaterina Trishkina,M. Dvorkin,Lawrence Panasci,Alexey Manikhas,Yaroslav Shparyk,Servando Cardona-Huerta,Kwok-Leung Cheung,Manuel Jesus Philco-Salas,Manuel Ruiz-Borrego,Zhimin Shao,Shinzaburo Noguchi,Jacqui Rowbottom,Mary Stuart,Lynda Grinsted,Mehdi Fazal,Matthew J. Ellis +17 more
TL;DR: Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients.
Journal ArticleDOI
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz,Fabrice Andre,Zefei Jiang,Zhimin Shao,Max S. Mano,Silvia P. Neciosup,Ling Min Tseng,Qingyuan Zhang,Kunwei Shen,Donggeng Liu,Lydia Dreosti,Howard A. Burris,Masakazu Toi,Marc Buyse,David Cabaribere,Mary Ann Lindsay,Shantha Rao,Lida Bubuteishvili Pacaud,Tetiana Taran,Dennis J. Slamon +19 more
TL;DR: The BOLERO-1 study assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer and in the subset of patients with hormone receptor-negative breast cancer at baseline.